CA2387529A1 - Biphenyl derivatives as nhe-3 inhibitors - Google Patents

Biphenyl derivatives as nhe-3 inhibitors Download PDF

Info

Publication number
CA2387529A1
CA2387529A1 CA002387529A CA2387529A CA2387529A1 CA 2387529 A1 CA2387529 A1 CA 2387529A1 CA 002387529 A CA002387529 A CA 002387529A CA 2387529 A CA2387529 A CA 2387529A CA 2387529 A1 CA2387529 A1 CA 2387529A1
Authority
CA
Canada
Prior art keywords
biphenyl
compounds
formula
nhe
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002387529A
Other languages
English (en)
French (fr)
Inventor
Dieter Dorsch
Peter Raddatz
Norbert Beier
Claudia Wilm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2387529A1 publication Critical patent/CA2387529A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002387529A 1999-09-22 2000-09-04 Biphenyl derivatives as nhe-3 inhibitors Abandoned CA2387529A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19945302A DE19945302A1 (de) 1999-09-22 1999-09-22 Biphenylderivate als NHE-3-Inhibitoren
DE19945302.0 1999-09-22
PCT/EP2000/008616 WO2001021582A1 (de) 1999-09-22 2000-09-04 Biphenylderivate als nhe-3-inhibitoren

Publications (1)

Publication Number Publication Date
CA2387529A1 true CA2387529A1 (en) 2001-03-29

Family

ID=7922831

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002387529A Abandoned CA2387529A1 (en) 1999-09-22 2000-09-04 Biphenyl derivatives as nhe-3 inhibitors

Country Status (16)

Country Link
EP (1) EP1214291A1 (de)
JP (1) JP2004500338A (de)
KR (1) KR20020033818A (de)
CN (1) CN1555356A (de)
AU (1) AU7649700A (de)
BR (1) BR0014199A (de)
CA (1) CA2387529A1 (de)
CZ (1) CZ2002815A3 (de)
DE (1) DE19945302A1 (de)
HU (1) HUP0202891A3 (de)
MX (1) MXPA02003087A (de)
NO (1) NO20021407L (de)
PL (1) PL355097A1 (de)
SK (1) SK3342002A3 (de)
WO (1) WO2001021582A1 (de)
ZA (1) ZA200203095B (de)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9932331B2 (en) 2014-07-25 2018-04-03 Taisho Pharmaceutical Co., Ltd. Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
EP3351248A1 (de) 2008-12-31 2018-07-25 Ardelyx, Inc. Verbindungen und verfahren zur inhibierung des nhe-vermittelten antiports bei der behandlung von mit flüssigkeitsretention und salzüberlastung assoziierten erkrankungen und erkrankungen des magen-darm-trakts
WO2019060051A1 (en) 2017-08-04 2019-03-28 Ardelyx, Inc. GLYCYRRHETINIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERKALIEMIA
US10272079B2 (en) 2013-04-12 2019-04-30 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
WO2020163642A1 (en) 2019-02-07 2020-08-13 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
DE10304374A1 (de) 2003-02-04 2004-08-05 Aventis Pharma Deutschland Gmbh Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
DE10341240A1 (de) 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102005001411A1 (de) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
EP2170872B1 (de) 2007-06-28 2010-09-01 Sanofi-Aventis U.S. LLC Verfahren zur herstellung von n-(2-chlor-4-methyl-3-thienyl)-1h-benzimidazol- 2-amin hydrochlorid und zwischenprodukte dafür
MX2011001821A (es) * 2008-09-02 2011-03-25 Sanofi Aventis Aminoindanos sustituidos y sus analogos, y el uso farmaceutico de los mismos.
HUE028394T2 (en) 2011-03-15 2016-12-28 Astellas Pharma Inc Guanidin Compound
CN103012200B (zh) * 2011-09-20 2014-12-17 北京大学 具有β-分泌酶抑制功能的化合物及其制备方法与应用
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548812A1 (de) * 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
DE19622222A1 (de) * 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
DE19737224A1 (de) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
DE19819548A1 (de) * 1998-04-30 1999-11-04 Merck Patent Gmbh Biphenylderivate

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
EP3351248A1 (de) 2008-12-31 2018-07-25 Ardelyx, Inc. Verbindungen und verfahren zur inhibierung des nhe-vermittelten antiports bei der behandlung von mit flüssigkeitsretention und salzüberlastung assoziierten erkrankungen und erkrankungen des magen-darm-trakts
EP3939964A1 (de) 2008-12-31 2022-01-19 Ardelyx, Inc. Kombinationen zur inhibierung des nhe-vermittelten antiports bei der behandlung von mit flüssigkeitsretention und salzüberlastung assoziierten erkrankungen und erkrankungen des magen-darm-trakts
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10940146B2 (en) 2013-04-12 2021-03-09 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
US10272079B2 (en) 2013-04-12 2019-04-30 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
EP3552630A1 (de) 2013-04-12 2019-10-16 Ardelyx, Inc. Nhe3-bindende verbindungen zur phosphattransporthemmung
EP3988120A1 (de) 2013-04-12 2022-04-27 Ardelyx, Inc. Nhe3-bindende verbindungen und verfahren zur phosphattransporthemmung
US9932331B2 (en) 2014-07-25 2018-04-03 Taisho Pharmaceutical Co., Ltd. Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2019060051A1 (en) 2017-08-04 2019-03-28 Ardelyx, Inc. GLYCYRRHETINIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERKALIEMIA
WO2020163642A1 (en) 2019-02-07 2020-08-13 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
EP4234016A2 (de) 2019-02-07 2023-08-30 Ardelyx, Inc. Glycyrrhetinsäurederivate zur behandlung von hyperkaliämie
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Also Published As

Publication number Publication date
WO2001021582A1 (de) 2001-03-29
CZ2002815A3 (cs) 2002-08-14
AU7649700A (en) 2001-04-24
PL355097A1 (en) 2004-03-22
ZA200203095B (en) 2003-09-23
EP1214291A1 (de) 2002-06-19
HUP0202891A3 (en) 2003-11-28
NO20021407D0 (no) 2002-03-21
MXPA02003087A (es) 2003-08-20
DE19945302A1 (de) 2001-03-29
CN1555356A (zh) 2004-12-15
BR0014199A (pt) 2002-05-21
SK3342002A3 (en) 2002-07-02
KR20020033818A (ko) 2002-05-07
HUP0202891A2 (hu) 2003-02-28
NO20021407L (no) 2002-03-21
JP2004500338A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
CA2387529A1 (en) Biphenyl derivatives as nhe-3 inhibitors
JP3802582B2 (ja) ペルフルオロアルキル−置換ベンゾイルグアニジン類、その製造方法、医薬または診断剤としてのその使用およびそれを含有する医薬
HUT60462A (en) Process for producing biphenyl derivatives and pharmaceutical compositions comprising same
IE67451B1 (en) Benzoylguanidines a process for their preparation their use as medicaments and medicaments containing them
JPH085848B2 (ja) カルボン酸エステル誘導体
IL107568A (en) Transformed amidino compounds, their preparation and pharmaceutical preparations containing them
PT659748E (pt) 1,1-dioxido-2h-1,2-benzotiazinoilguanidina substituidas, processo para a sua preparacao, sua utilizacao como medicamento ou meio de diagnostico bem como medicamento que as contem.
CA2471524A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
HU217635B (hu) Orto-szubsztituált benzoil-guanidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
PL179395B1 (pl) kwasów alkenylokarboksylowych, sposób ich wytwarzaniaoraz srodek leczniczy zawierajacy fenylopodstawione guanidydy kwasów alkenylokarboksylowych zawierajace grupy perfluoroalkilowe PL PL PL PL
NZ542608A (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
AU750472B2 (en) Biphenyl derivatives
KR20010086085A (ko) 이미다조[４,５-ｃ]-피리딘-４-온-유도체
EP0676396A1 (de) Tetrazolylphenyl-Pivalat-Derivate und diese als wirksamer Teil enthaltende medizinische Zusammensetzung
AU704630B2 (en) Arylbenzoylguanidines
NO300264B1 (no) Substituerte benzoylguanidiner, deres anvendelse som medikament samt medikament inneholdende disse
CZ2003671A3 (cs) Derivát bifenylu, způsob jeho přípravy, jeho použití jako integrinových inhibitorů a farmaceutický prostředek, který ho obsahuje
US4385047A (en) Antiallergic imidodisulfamides
TW400320B (en) A benzoylguanidine compound having Na<+>/H<+> exchanger inhibitory activity, its preparation processes and the pharmaceutical compositions comprising the same
US3474134A (en) Phenoxyethyl-guanidines and the salts thereof
CZ20004026A3 (cs) Derivát bifenylu, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje
MXPA00010416A (en) Biphenyl derivatives
AU2008274655A1 (en) Malonamide derivatives with antithrombotic activity
PT702001E (pt) Benzoilguanidinas substituidas por trifluorpropilo e sua utilizacao como medicamento ou meio de diagnostico
CA2646204A1 (en) Substituted 2-amino-4-phenyl-dihydroquinolines, method for the production thereof, use thereof as medicaments, and medicaments containing them

Legal Events

Date Code Title Description
FZDE Discontinued